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Background: Interventional clinical studies conducted in the regulated drug research environment are reported
using International Council for Harmonisation (ICH) regulatory guidance documents: ICH E3 on the structure and
content of clinical study reports (CSRs) published in 1995 and ICH E3 supplementary Questions & Answers (Q & A)
published in 2012.
Since the ICH guidance documents were published, there has been heightened awareness of the importance of
disclosure of clinical study results. The use of the CSR as a key source document to fulfil emerging obligations has
resulted in a re-examination of how ICH guidelines are applied in CSR preparation. The dynamic regulatory and
modern drug development environments create emerging reporting challenges.
Methods: Regulatory medical writing and statistical professionals developed Clarity and Openness in Reporting:
E3-based (CORE) Reference over a 2-year period. Stakeholders contributing expertise included a global industry
association, regulatory agency, patient advocate, academic and Principal Investigator representatives.
Results: CORE Reference should help authors navigate relevant guidelines as they create CSR content relevant for
today’s studies. It offers practical suggestions for developing CSRs that will require minimum redaction and
modification prior to public disclosure.
CORE Reference comprises a Preface, followed by the actual resource. The Preface clarifies intended use and
underlying principles that inform resource utility. The Preface lists references contributing to development of the
resource, which broadly fall into ‘regulatory’ and ‘public disclosure’ categories. The resource includes ICH E3 guidance
text, ICH E3 Q & A 2012-derived guidance text and CORE Reference text, distinguished from one another through the
use of shading. Rationale comments are used throughout for clarification purposes.
A separate mapping tool comparing ICH E3 sectional structure and CORE Reference sectional structure is also provided.
Together, CORE Reference and the mapping tool constitute the user manual.
Conclusions: This publication is intended to enhance the use, understanding and dissemination of CORE Reference.
The CORE Reference user manual and the associated website (http://www.core-reference.org) should improve the
reporting of interventional clinical studies.
Periodic updates of CORE Reference are planned to maintain its relevance.
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Keywords: Reporting guidelines, Reporting standards, Randomised controlled trials, Information dissemination,
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The current International Council for Harmonisation
(ICH) regulatory guidance documents for clinical study re-
ports (CSRs) are ICH E3 [1] (effective 1995) and the ICH
E3 2012 supplementary Questions & Answers (Q & A)
document [2]. The 2012 Q & A document addresses some
of the ambiguity inherent to ICH E3. Interpretational texts
on the effective use of clinical regulatory guidance docu-
ments form an integral part of the clarifying process for
guideline end-users [3–5]. We similarly intend Clarity and
Openness in Reporting: E3-based (CORE) Reference to
provide interpretational support of the guidelines and prag-
matic suggestions for preparing CSRs.
In addition, recently mandated public disclosure of CSRs
submitted in Europe for regulatory review requires [6] that
the clinical research community understands the complex
concepts around public disclosure of clinical-regulatory
documents and implements appropriate practical solutions
in order to minimise associated risks, which are largely
privacy-related [7]. The CSR is the first clinical-regulatory
document type to be disclosed. The experiences of both
applicants and regulators in these formative times are
expected to shape future direction in this area. Therefore,
resources that support this early learning process should
be of value to the global clinical research community.
The objective of this project was to create a user manual
to help medical writers navigate relevant guidelines as they
create CSR content for today’s studies. The main resource,
CORE Reference, was based on the long-standing experi-
ences of clinical research professionals who report clinical
studies using the ICH guidelines, and extensive literature
review, followed by a structured approach to develop inter-
nationally based consensus. The findings were aggregated
and include extensive information to support resource util-
ity, detailed content suggestions and practical suggestions
for developing CSRs that will require minimum redaction
and modification prior to public disclosure. A separate
mapping tool comparing ICH E3 and CORE Reference
sectional structure supports the resource. CORE Reference
and the mapping tool constitute the user manual.Methods
Composition of the BWG
In May 2014, at the European Medical Writers Associ-
ation (EMWA) Conference in Budapest, the lead author
of CORE Reference and EMWA Vice President (SH)
convened the Budapest Working Group (BWG), a groupof experts from the Medical Writing community, to ad-
dress current controversies and limitations in the field of
reporting clinical studies and offer potential solutions. The
BWG are the authors of CORE Reference and of this
publication and include members of EMWA and the
American Medical Writers Association (AMWA) to en-
sure representation for the EU and USA. The group
comprises experts in ICH E3, CSR templates, CSR authoring
and the public disclosure of clinical-regulatory documents.
These individuals are employees of a pharmaceutical
company, contract research organisations and freelancers,
brought together in an attempt to represent the range
of perspectives of professionals commonly engaged in
authoring clinical-regulatory documents. A statistician
and clinical pharmacologist, both members of Statisticians
in the Pharmaceutical Industry (PSI), joined the BWG in
June 2014, to ensure that all areas have expert input.
There was no official involvement of PSI. In December
2014, the first open-access publication about this project
was published [8]. In February 2015, AMWA officially
joined EMWA as equal partners, and shortly afterwards,
CORE Reference was registered with EQUATOR [9]. All
authors gave their time and expertise to this project,
voluntarily and without financial compensation, in the
belief that an open-access user manual to support clinical
study reporting would benefit today’s healthcare industry.
Further information on individual author contributions
is included in the ‘Authors’ information’ section.Project plan
In the original project plan [8], we described our intention
to review the existing guidelines for CSR and clinical study
protocol (CSP) authoring and develop internationally
based consensus by involvement of relevant stakeholders.
The planning and conduct of this project closely followed
the AGREE II Instrument recommendations [10]. During
the 2-year project, the BWG took a pragmatic and re-
sponsive approach to challenges presented by a dynamic
professional environment.
Emerging awareness of a parallel and more mature
CSP effort [11] prompted the decision to discontinue our
planned CSP workstream and instead support the efforts
of colleagues outside our group.
The 2-year Roadmap [8] summarises the BWG’s
planned and conducted de novo and oversight reviews.
The stakeholders (described in detail below) included rep-
resentatives from a global industry association, regulatory
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Investigator, who reviewed the CORE Reference resources,
and provided insights and analysis over the period March
2015 to February 2016.
Multiple, extensive and rigorous literature searches
were conducted throughout the 2-year project to support
the broad aim of integrating relevant global and regional
(EU and USA) regulatory guidance into the resource. Due
diligence was exercised throughout and to the best ability
of the BWG.
Development of the user manual
The original work package submitted for stakeholder
comment in March 2015 took the form of separate
concurrently prepared ‘Text’ (i.e. recommendations for
CSR authoring) and ‘Rationales’ (i.e. rationales for and
clarifications of the reasons for each recommendation)
documents, as well as a mapping tool. The mapping
tool, prepared on completion of the Text and Rationales
documents, compared ICH E3 and CORE Reference sec-
tional numbering. The original Text document included a
limited introduction section. During the stakeholder com-
ment period (March to June 2015), the BWG decided that
a single consolidated ‘Text and Rationales’ document
prefaced by a scope-enhanced introduction would im-
prove understanding and utility of the final resource.
BWG progressed this reconstruction during the stake-
holder comment period, during which the stakeholders
independently arrived at a similar conclusion, and rec-
ommended to the BWG a merging of the planned Text
and Rationales documents. The final published user man-
ual comprises CORE Reference (a single document in-
cluding an extensive ‘Preface’ followed by merged text,
rationales and clarifications), as well as the separate map-
ping tool. Stakeholders took a further opportunity to com-
ment on a pre-publication version of CORE Reference in
February 2016. As a result, further format enhancements
were made. Finally, in March 2016, following EMA’s
publication of guidance [7] on the implementation of
Policy 0070 [6], the BWG updated CORE Reference ac-
cordingly. The period March 2016 to the end of April
2016 was spent finalising (including quality control and
proofreading steps) the user manual and website and
this publication.
To allow rapid dissemination of periodic project up-
dates, the planned December 2015 publication [8] was
replaced with online video posting of project updates
presented at the EMWA conferences in Dublin (06
May 2015) [12] and The Hague (06 November 2015)
[13]. A similar presentation to that made in The Hague
was made at the AMWA conference in San Antonio,
TX, USA (01 October 2015).
The idea for a website to house the resource and sup-
port its utility, and logos to brand the resource and theBWG, came from an online search of similar projects.
Many of the CORE Reference web design ideas were in-
fluenced by the website of the STROBE Statement [14].
Other than the described process and procedural
changes to the original plans, the broad aims set out at
the start of this project have been fulfilled through the
final published resource, and the planned 2-year project
timeline has been met. CORE Reference is available at
http://www.core-reference.org. This publication describes
the project and the launch of CORE Reference and is
intended to enhance the use, understanding and dissemin-
ation of CORE Reference.
Contributors to development of CORE Reference
Stakeholder: Health Canada
Consolidated comments for consideration were provided
by Dr Celia Lourenco (Director, Bureau of Gastroenter-
ology, Infection and Viral Diseases, Therapeutic Products
Directorate Health Products and Food Branch), whose
team of four contributors provided a high-level review of
the documentation.
Stakeholder: Drug Information Association Medical Writing
Community
The Community Chair, David Clemow (Lilly USA, LLC),
on behalf of the Community’s 18-member CORE Review
Task Force, provided anonymised comments from the
task force members for consideration (several of whom
had served on the ICH E3 2012 Q & A Implementation
Working Group).
Stakeholder: Academic and Principal Investigator
Todd E. Pesavento, MD, Professor of Medicine, Medical
Director of Solid Organ Transplantation, Ohio State
University, USA, provided detailed comments for
consideration.
Stakeholder: Patient advocate




CORE Reference and the mapping tool constitute the user
manual (Fig. 1). CORE Reference is provided as a PDF.
The separate mapping tool comparing ICH E3 sectional
structure and CORE Reference sectional structure is
provided in spreadsheet format to support its utility.
CORE Reference presents content suggestions and
best practices that add value for medical writers creating
ICH-compliant CSRs, but these come with the caveat
that they may not work in all situations. CSR authors
should use their judgement and, above all, make sensible
structuring choices based on their particular study. This
Fig. 1 Process map of the CORE Reference project. AMWA American Medical Writers Association, BWG Budapest Working group, CORE Reference
Clarity and Openness in Reporting: E3-based, EMWA European Medical Writers Association, ICH International Council for Harmonisation, ICH E3 ICH
Harmonised Tripartite Guideline: Structure and Content of Clinical Study Reports E3. Step 4. 30 Nov 1995; ICH E3 2012 Q & A ICH E3 Guideline:
Structure and Content of Clinical Study Reports Questions & Answers (R1). 6 July 2012. 'Project Plan' publication: http://dx.doi.org/10.1179/
2047480614Z.000000000254; 'Publication and Launch' publication: http://dx.doi.org/10.1186/s41073-016-0009-4
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than a template. In addition, although we intend CORE
Reference to be globally relevant, we include links to
relevant regional (EU and USA) guidance and other useful
resources where possible, with explanation, to maximise
utility of the resource. Consultation with the relevantregulatory agency or body is highly recommended in cases
where there is doubt.
The latest available guidance on public disclosure of
clinical-regulatory documents [6, 7] are integrated into
CORE Reference through discrete colour-coded com-
ments prompting the user to consider both the ‘primary
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for public disclosure) CSR. These discrete comments
incorporated into CORE Reference should help CSR
authors make informed choices as they navigate the
evolving and complex area of redaction of sensitive in-
formation prior to public disclosure.
CORE Reference: Clarity
ICH E3 and ICH E3 2012 Q & A update guidance text is
presented in CORE Reference. Commonly perceived am-
biguities in the ICH E3 guidance that were not addressed
by the ICH E3 2012 Q & A update are addressed in CORE
Reference. In addition, relevant regional (EU and USA)
regulatory guidance are included. Further value-added in-
sights, based on the extensive collective experience of the
BWG and stakeholders, are included.
CORE Reference comprises ICH E3 guidance text,
ICH E3 Q & A 2012-derived guidance text and CORE
Reference text, distinguished from one another through
the use of monochrome shading. All ICH E3 guidance
text is either included as original wording; or is included
as modified wording and the modification is explained;
or is omitted, the omission is shown and the reason for
the omission is explained. All ICH E3 Q & A 2012-
derived guidance text is included and explained. Ration-
ale comments—in ‘comment balloon’ format on the
right-hand side of each page—are used for explanation
and clarification purposes. A key explaining text shad-
ing and comments is included in the footer of each
page of CORE Reference.
Where alternative presentations of the same informa-
tion would work equally well in a CSR, they are shown
with an explanation provided in the Rationale comments
to allow CSR authors to make informed authoring
choices relevant for their particular study.
A separate mapping tool comparing ICH E3 sectional
structure and CORE Reference sectional structure is also
provided to support the utility of CORE Reference.
CORE Reference technical format supports on-screen
and print readability, with even the most basic printer
hardware.
CORE Reference: Openness
The global pharmaceutical industry agrees that the prin-
ciples of responsible clinical trial data sharing must be
upheld. The Pharmaceutical Research and Manufacturers
of America (PhRMA) and the European Federation of
Pharmaceutical Industries and Associations (EFPIA) is-
sued joint Principles for Responsible Clinical Trial Data
Sharing in January 2014 [15], followed by the Institute of
Medicine who issued their report ‘Sharing Clinical Trial
Data: Maximizing Benefits, Minimizing Risk’ in January
2015 [16]. The World Health Organization (WHO) en-
courages data-sharing initiatives in their April 2015statement ‘Public Disclosure of Clinical Trial Results’ [17].
Further, in January 2016, the International Committee of
Medical Journal Editors proposed manuscript publication
requirements to help meet the obligation to responsibly
share data generated by interventional clinical trials [18].
Initial limited public disclosure of study data is on-
going, with potential for expansion, in some parts of the
world. The European Commission Guidance of 2006 re-
quires mandatory posting of clinical trial results using the
European Union Drug Regulating Authorities Clinical
Trials database [19]. Title VIII of the Food and Drug
Administration Amendments Act of 2007 [20] requires
the registration and submission of summary results in-
formation to ClinicalTrials.gov for certain clinical trials
of drugs (including biologic products) and devices. Changes
to the rule to ‘…enhance patient enrolment, provide a
mechanism to track subsequent progress of clinical trials,
provide more complete results information, and enhance
patient access to and understanding of the results of clinical
trials’ were proposed on 21 November 2014 and opened for
public comment (period ended 23 March 2015) [21]. There
is no published timetable for enactment of changes to the
rule.
With respect to privacy protections, selected references
are presented below. In the USA, the Health Insurance
Portability and Accountability Act (HIPAA) governs pro-
tected health information [22, 23], and the Department of
Health and Human Services has also issued guidance
[24]. In the European Union, Directive 95/46/EC of the
European Parliament and of the Council covers protec-
tion of personal information [25]. In addition, the World
Medical Association has issued guidance on privacy [26],
and the Council of Europe Convention for the Protection
of Individuals with regard to Automatic Processing of
Personal Data also addresses protections [27]. The
International Organization for Standardization (ISO)/TS
14265:2011 [28] provides a framework for classifying the
various specific purposes that can be defined and used by
individual policy domains (e.g. healthcare organisations,
regional health authorities, jurisdiction countries) as an aid
to the consistent management of information in the deli-
very of healthcare services and for the communication of
electronic health records across organisational and jurisdic-
tional boundaries. In Canada, the Health Privacy Act 2011–
2012 [29] governs disclosure of personal information.
There are many country- and region-specific legislative
directives that address protection of personal information.
Some elements may not be entirely consistent; however,
the general governing principles are very similar. There
are other privacy protections that apply according to local
jurisdiction, and we strongly advise to review the guid-
ance(s) in force in applicable regions.
Requirements for broader public disclosure of trial data
are mandated through the European Medicines Agency
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dicinal products for human use [6] since 01 January 2015.
Policy 0070 mandates that from 01 July 2015, CSRs from
extension of indication and line extension applications are
made publicly available, bringing them into alignment
with CSRs in new marketing authorisation applications,
which were made publicly available from 01 January 2015.
Sponsors may take differing approaches to ensure
their CSRs comply with evolving responsible data sharing
requirements and industry standards. Using CORE Ref-
erence as a resource for CSR authoring is one way to
encourage sharing of best practices.
Increased requirements for data disclosure through
CSR publication mean that medical writers must now
consider the CSR as a single document with two uses,
each with a distinct purpose and audience:
 The ‘primary use CSR’ (the EMA term for which is
scientific review version1) is a technical document
for regulatory review and comprises full CSR text
and all CSR appendices. The information reported
must not constrain the review process.
 The ‘secondary use CSR’ (the EMA term for which
is redacted clinical report1) is for public disclosure
and comprises redacted CSR text and selected
appendices. Sensitive information presented in the
‘primary use CSR’ is redacted in the ‘secondary use
CSR’.
The technical ‘primary use CSR’ has a primary audi-
ence comprising regulators and pharmaceutical industry
professionals, and its derived and summary information
are of interest to health technology assessment and
marketing professionals. CSRs must support the decision-
making process for the licensing of medicines, and the
data reported must not constrain this process. The CSR
also has a secondary audience associated with public dis-
closure following the marketing authorisation decision.
Some data germane to regulatory review—and presented
in the ‘primary use CSR’—may present risks if released
directly into the public domain. This creates a need for a
‘secondary use CSR’ in which sensitive data are redacted,
as described in the EMA’s March 2016 guidance on im-
plementation of Policy 0070 [7]. The risks are largely
associated with privacy. In addition, any single CSR repre-
sents only a portion of the data accrued in the course of
research and development and may not represent the ag-
gregate knowledge associated with the new medicine or
indication.
If, in the ‘primary use CSR’, subject data are reported
with care to protect sensitive information, this will
streamline redaction in the ‘secondary use CSR’. This
‘proactive’ approach, first proposed by the BWG [8], is
encouraged by the March 2016 EMA guidance onimplementation of Policy 0070 [7]. These principles
underlie CORE Reference recommendations and sugges-
tions. CORE Reference guides the CSR author on cre-
ation of the ‘primary use CSR’ text, including practical
suggestions for safeguarding patient anonymity and also
on protection of the identity of individuals involved in
the management, conduct and reporting of clinical stud-
ies, in such a way as to not constrain the process of
regulatory review of the ‘primary use CSR’. CORE Refer-
ence gives separate attention to the topic of redaction of
sensitive data necessary for creation of a ‘secondary use
CSR’ fit for public audiences. Where it is possible to
annex or append data in the ‘primary use CSR’ that may
require subsequent redaction, practical placement sug-
gestions are made to minimise or avoid altogether the
piecemeal redaction of data in the CSR body that might
otherwise be necessary.
CORE Reference: Reporting: E3-based
The ICH E3 Q & A 2012 [2] document restates un-
equivocally that ICH E3 [1] is a guidance document and
not a template. Similarly, CORE Reference is a user
manual and not a template. CORE Reference offers sug-
gestions for content but does not mandate a particular
sequence or organisation of the individual CSR sections.
However, to allow easy mapping to the original ICH E3
guidance document and to avoid conflict with guidance
documents that refer to ICH E3 sectional numbering,
CORE Reference maintains the level 1 heading hierarchy
of ICH E3. It remains at the author’s discretion to decide
on the most appropriate CSR structure. The content
suggestions are intended to facilitate optimal reporting
for the extended range of study designs commonly en-
countered in modern drug development—in addition to
the universal study design elements of safety and efficacy,
as laid out in ICH E3.
A separate CORE Reference/ICH E3 sectional map-
ping tool is provided to help medical writers understand
suggested placement of content.
Discussion
In December 2014, 7 months into this 2-year project, we
published our project plan [8], which included an explan-
ation of our ‘proactive approach’ to the complex area of
CSR disclosure: ‘Industry is currently debating a two-step
process for submitting and then publishing clinical
study results. The two-step process involves producing
a submission-ready CSR that may contain data that
must be removed after submission to produce the final
disclosure-ready CSR. We propose that the CSR should
be as disclosure-ready as possible from the outset to
safeguard against inadvertent identification of participants,
assure optimally timed public disclosure of clinical trial re-
sults, and be as cost efficient as possible.’ This ‘proactive
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states: ‘EMA understands that in an initial phase redaction
techniques are likely to be used by applicants/marketing
authorisation holders (MAHs), taking into account that
for a certain period, pharmaceutical companies will have
to anonymise their data retrospectively (reactive data
anonymisation), i.e. after the clinical report has already
been submitted for scientific review. Importantly, redac-
tion alone is more likely to decrease the clinical utility of
the data compared to other techniques. Therefore, EMA
is of the view that applicants/MAHs, after experience
has been accumulated in the de-identification of clinical
reports, should transition to other anonymisation tech-
niques that are more favoured in order to optimise the
clinical usefulness of the data published (proactive data
anonymisation). Pharmaceutical companies are encour-
aged to use these anonymisation techniques as soon as
possible, whilst ensuring data anonymisation is achieved.’
CORE Reference should therefore not only expedite
the move towards EMA’s intended goal of a heavily ‘pro-
active approach’ to anonymisation but may also contrib-
ute to increased trust derived from this approach, which
should reduce the need for piecemeal redaction of indi-
vidual words and phrases throughout a document.
In addition, time, money and cost savings in the devel-
opment of CSRs for their primary and secondary uses
should be possible [8].
Furthermore, CORE Reference should increase the qual-
ity of final CSRs and enhance consistency within and be-
tween sponsors. It may also benefit systematic reviewers
in their use of CSRs, which will also contribute to the de-
velopment of a trust-enhanced environment.
The website is fitted with separate download counters
for CORE Reference and the mapping tool. Although
this will enable us to monitor resource downloads, it is
less easy to monitor the use of CORE Reference in prac-
tice. We therefore encourage user feedback via both a
‘Contact’ and a ‘Support’ page.
CORE Reference is open for comments for a 6-week
period from its publication date. Comments may be sub-
mitted via http://www.core-reference.org.
To maintain its relevance, surveillance of the evolving
regulatory and public disclosure landscapes will support
periodic update of CORE Reference.Conclusions
This publication is intended to enhance the use, under-
standing and dissemination of CORE Reference.
The CORE Reference user manual and the associated
website (http://www.core-reference.org) should improve
the reporting of interventional clinical studies.
Periodic updates of CORE Reference are planned to




Availability of data and materials
Not applicable.
Endnotes
1External guidance on the implementation of the
European Medicines Agency policy on the publication of
clinical data for medicinal products for human use. 2
March 2016. (http://www.ema.europa.eu/docs/en_GB/
document_library/Regulatory_and_procedural_guideline/
2016/03/WC500202621.pdf [Accessed 04 March 2016]).
Chapter 2, Section 3.3.1.9 states the cover letter including
declaration will include ‘Confirmation that the clinical re-
ports submitted for scientific evaluation are the same as
that submitted for publication…except for the redactions’.
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